

Decision Points for the 48th Board Meeting

Master List

Version 17 November 2022

#	Decision
1	Approval of the Agenda
2	Approval of the Rapporteur
3	Extension of the COVID-19 Response Mechanism (C19RM)
4	Sources and Uses of Funds for the 2023–2025 Allocation Period
5	2023 Work Plan and Budget Narrative and the 2023 Operating Expenses Budget
6	2023-2028 M&E Framework, KPI Framework and Multi-Year Evaluation Calendar
7	Advancement of Non-Global Fund-Financed Procurement Utilizing the Pooled Procurement Mechanism and wambo.org

Approval of the Agenda

Decision Point GF/B48/DP01: Approval of the Agenda

The Agenda for the 48th Board Meeting (GF/B48/01 - Revision 2) is approved.

Signed:

Erika Satterwhite
Rapporteur

Susie Rhee
Secretariat

Approval of the Rapporteur

Decision Point GF/B48/DP02: Approval of the Rapporteur

Erika Satterwhite from the Private Sector Constituency is designated as Rapporteur for the 48th Board Meeting.

Signed:

Erika Satterwhite
Rapporteur

Susie Rhee
Secretariat

Extension of the COVID-19 Response Mechanism (C19RM)

Decision Point GF/B48/DP03: Extension of the COVID-19 Response Mechanism (C19RM)

1. The Board acknowledges that C19RM was established to support (i) COVID-19 control and containment interventions, (ii) COVID-19 risk-related mitigation measures for programs to fight HTM, and (iii) expanded reinforcement of key aspects of health systems, and recognizes that C19RM requests and awards through the end of 2021 largely focused on the acute response to the COVID-19 pandemic;
2. The Board acknowledges that the pandemic is evolving, and that recipient priorities are correspondingly shifting towards longer-term investments in health systems' infrastructure and capacities for pandemic preparedness and response;
3. To facilitate careful planning of such investments, including alignment with potential funding requests for the Seventh Replenishment grant cycle, the Board approves that C19RM funds may be awarded through 30 June 2023, with opportunity for subsequent C19RM portfolio optimization awards;
4. To enable maximization of impact from investments in resilient and sustainable systems for health, the Board approves that any C19RM funds may be implemented through 31 December 2025 and will finance interventions across the Sixth and Seventh Replenishment periods – acknowledging that the Secretariat will continue to ensure rapid deployment of funds and quality implementation notwithstanding this deadline;
5. The Board approves that C19RM funding requests will continue to be developed through appropriate, multi-sectoral consultation and fully inclusive decision-making, which must engage communities and civil society, and which must ensure coordination with the national COVID-19 response coordinating body or provide other evidence of alignment with the national approach to COVID-19 response in the absence of such a coordinating body;
6. The Board approves that the Secretariat may use up to 4.5% of C19RM funds, representing an increase from the prior ceiling of 3%, to cover additional management and operating costs related to extension of C19RM; and
7. The Board agrees that all other parameters of C19RM under GF/B46/EDP06 remain unchanged.

Budgetary implications (included in, or additional to, OPEX budget):

Incremental management and operating costs directly attributable to C19RM will be covered by up to 4.5% of any funds made available for C19RM.

Signed:

Erika Satterwhite

Rapporteur

Susie Rhee

Secretariat

Sources and Uses of Funds for the 2023–2025 Allocation Period

Decision Point GF/B48/DP04: Sources and Uses of Funds for the 2023–2025 Allocation Period

1. Based on the recommendation of the Audit and Finance Committee (AFC), as presented in GF/B48/03A – Revision 1, the Board approves US\$ 12.903 billion as sources of funds for allocation for the 2023-2025 allocation period. The total amount of sources of funds for allocation comprises, in accordance with the Comprehensive Funding Policy set forth in Annex 1 to GF/B36/02 – Revision 1 and approved through decision point GF/B36/DP04:
 - i. US\$ 13.678 billion, derived from the announced replenishment results for the Seventh Replenishment, net of adjustments;
 - ii. US\$ 0.250 billion of forecasted unutilized funds from the 2020-2022 allocation period; and
 - iii. a deduction of US\$ 1.025 billion of forecasted aggregate operating expenses for the 2023-2025 allocation period.
2. Based on the recommendation of the Secretariat to supplement the recommendation of the Strategy Committee, as presented in GF/B48/03A – Revision 1, the Board approves the use of an additional US\$ 0.200 billion for catalytic investments for the 2023-2025 allocation period, bringing the total amount, from sources of funds for allocation, for catalytic investments for the 2023-2025 allocation period to US\$ 0.400 billion, to be made available for the priorities and associated costs set forth in Annex 1 of GF/B48/03A-Revision 1, and based on the recommendation of the Secretariat, the Board approves updating the delegated authority to the Secretariat established in paragraph 7 of GF/B47/DP06 so that the Secretariat may increase the amount of funding available for the Emergency Fund by up to an additional US\$ 0.020 billion, using funding approved as available by the AFC for portfolio optimization.
3. Additionally, based on the recommendation of the AFC and to help ensure the maximum amount of impact and use of funds over the 2023-2025 allocation period, the Board requests that the Secretariat include an additional US\$ 0.625 billion in the amount used to determine country allocations pursuant to the allocation methodology for the 2023-2025 allocation period in accordance with decision point GF/B47/DP05 (Allocation Methodology).
4. Accordingly, the Board approves that the amount of sources of funds for country allocations for the 2023-2025 allocation period is US\$ 12.503 billion, to which US\$ 0.625 billion will be added prior to determining the country allocation, for a total of US\$ 13.128 billion, to be used in accordance with the Allocation Methodology and decision point GF/B47/DP05.

Signed:

Erika Satterwhite
Rapporteur

Susie Rhee
Secretariat

2023 Work Plan and Budget Narrative and the 2023 Operating Expenses Budget

Decision Point GF/B48/DP05: 2023 Work Plan and Budget Narrative and the 2023 Operating Expenses Budget

Based on the recommendation of the Audit and Finance Committee (AFC), and the recommendation of the Secretariat to supplement the AFC's recommendation, the Board approves the following:

- i. the 2023 Work Plan and Budget Narrative, as set forth in GF/B48/02A – Revision 1; and
- ii. the 2023 Operating Expenses Budget in the amount of US\$ 340 million (comprising (i) PART A Secretariat Operating Expenses of US\$ 272 million, which includes US\$ 16.5 million for the Office of the Inspector General's 2023 Operating Expenses; and (ii) PART B In-Country and Independent Bodies of US\$ 68 million), as set forth in GF/B48/02A – Revision 1.

Signed:

Erika Satterwhite
Rapporteur

Susie Rhee
Secretariat

2023-2028 M&E Framework, KPI Framework and Multi-Year Evaluation Calendar

Decision Point GF/B48/DP06: 2023-2028 M&E Framework, KPI Framework and Multi-Year Evaluation Calendar

1. The Board acknowledges and appreciates the extensive work across the partnership to incorporate past lessons into development of an improved holistic approach to Monitoring and Evaluation (M&E) for the new Strategy. The Board notes the recommendations of the Strategy Committee (SC) and Audit and Finance Committee (AFC), as set forth in GF/B48/04 and:
 - i. Endorses the components of the M&E Framework as described in GF/B48/04 Annex 1;
 - ii. Approves the KPI Framework (including each Key Performance Indicator), as set forth in GF/B48/04 Annex 2;
 - iii. Approves the topics for the Multi-Year Evaluation Calendar 2023-2028 as set forth in GF/B48/04 Annex 3; and
 - iv. Delegates authority to the SC to approve changes to the Multi-Year Evaluation Calendar in 2023, following a request by the Chief Evaluation and Learning Officer and advice from the Independent Evaluation Panel.

Budgetary implications (included in, or additional to, OPEX budget)

Budget for the Independent Evaluation Function is included in the 2023 OPEX and will be requested annually in line with approved workplans. No specific budgetary implication for the implementation of the KPI Framework.

Signed:

Erika Satterwhite
Rapporteur

Susie Rhee
Secretariat

Decision Point GF/B48/DP07: Advancement of Non-Global Fund-Financed Procurement Utilizing the Pooled Procurement Mechanism and wambo.org

The Board:

1. recalls its approval of a pilot for procurement of health and non-health products via wambo.org for eligible buyers using domestic and other non-Global Fund sources of funding as detailed in GF/B37/DP09 and GF/B42/DP05; and its request that the Secretariat include the results of an evaluation of the pilot in the development of a strategy for future advancement of wambo.org to be presented for Board approval no later than November 2022;
2. notes the Technical Evaluation Reference Group (“TERG”) evaluation findings and recommendations concerning the pilot discussed at the 18th meeting of the Strategy Committee; and
3. understands that the Secretariat will explore appropriate solutions for the challenges raised by the TERG evaluation and continue to facilitate access to products through wambo.org, while in parallel working to strengthen the capacities of regional and national procurement channels to ensure value for money and options for access to quality-assured health products for countries.

Therefore, based on the Strategy Committee’s recommendation and in support of the proposed approach for non-Global Fund financed procurements, as detailed in GF/B48/05, the Board approves:

1. The Secretariat’s continued operationalization of the current scope of non-Global Fund-financed orders by governments and non-government development organizations in Global Fund-eligible and transitioned countries, for products and services as they become available on wambo.org;
2. Removing any cap related to non-Global Fund-financed orders; and
3. Incorporating reporting on the non-Global Fund-financed procurement mechanism into annual updates to the Board on NextGen Market Shaping implementation

Budgetary implications (included in, or additional to, OPEX budget)

Costs associated with operationalization of continuation of the non-Global Fund-financed procurement mechanism are estimated at up to USD 350,000 per year for incremental and ongoing operating costs related to information technology and staff. Following Board approval, these estimated costs will be incorporated, as appropriate, into the OPEX budget.

Signed:

Erika Satterwhite
Rapporteur

Susie Rhee
Secretariat